003580.KS
NEXT SCIENCE Co., Ltd. [003580.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
003580.KS Stock Summary
Top 10 Correlated ETFs
003580.KS
Top 10 Correlated Stocks
003580.KS
In the News
003580.KS Financial details
Company Rating
Sell
Market Cap
343.67B
Income
-23.5B
Revenue
79.87B
Book val./share
1166.3
Cash/share
232.44
Dividend
-
Dividend %
-
Employees
95
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-11.07
Forward P/E
-
PEG
-2.06
P/S
2.77
P/B
3.59
P/C
31.1
P/FCF
-12.75
Quick Ratio
-
Current Ratio
0.9
Debt / Equity
0.8
LT Debt / Equity
0.15
-
-
EPS (TTM)
-554.68
EPS next Y
-
EPS next Q
-
EPS this Y
49.22%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-10.45%
Revenue last 5Y
17.92%
Revenue Q/Q
-18.54%
EPS Q/Q
138.5%
-
-
-
-
SMA20
7.06%
SMA50
29.93%
SMA100
102.18%
Inst Own
-
Inst Trans
-
ROA
-14%
ROE
-29%
ROC
-0.21%
Gross Margin
40%
Oper. Margin
-24%
Profit Margin
-25%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3390.0-9600.0
52W High
-24.69%
52W Low
+113.27%
RSI
52
Rel Volume
0.3
Avg Volume
1.55M
Volume
464.22K
Perf Week
-0.28%
Perf Month
18.91%
Perf Quarter
97.81%
Perf Half Y
83.74%
-
-
-
-
Beta
0.093
-
-
Volatility
183.15%, 591.57%
Prev Close
-0.28%
Price
7230
Change
0%
003580.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.43K | 1.12K | 1.17K | 1.06K | 1.89K | |
| Net income per share | -934.88 | -897.79 | -340.43 | -360.78 | -538.35 | |
| Operating cash flow per share | -262.34 | -421.28 | -155.09 | -191.23 | -300.08 | |
| Free cash flow per share | -289.53 | -695.92 | -197.5 | -238.49 | -326.19 | |
| Cash per share | 985.89 | 715.68 | 1.11K | 677.61 | 232.46 | |
| Book value per share | 3.09K | 2.08K | 2.8K | 1.51K | 1.17K | |
| Tangible book value per share | 2.9K | 1.75K | 2.51K | 1.25K | 674.76 | |
| Share holders equity per share | 3.09K | 2.08K | 2.8K | 1.51K | 1.17K | |
| Interest debt per share | 1.36K | 1.13K | 963.5 | 990.29 | 1.07K | |
| Market cap | 197.9B | 170.86B | 837.74B | 223.51B | 216.92B | |
| Enterprise value | 205.43B | 187.61B | 861.74B | 244.43B | 247.42B | |
| P/E ratio | -8.65 | -6.01 | -64.04 | -14.66 | -9.51 | |
| Price to sales ratio | 5.65 | 4.83 | 18.6 | 5.01 | 2.72 | |
| POCF ratio | -30.84 | -12.82 | -140.57 | -27.66 | -17.06 | |
| PFCF ratio | -27.94 | -7.76 | -110.38 | -22.18 | -15.7 | |
| P/B Ratio | 2.62 | 2.6 | 7.78 | 3.5 | 4.39 | |
| PTB ratio | 2.62 | 2.6 | 7.78 | 3.5 | 4.39 | |
| EV to sales | 5.87 | 5.3 | 19.13 | 5.48 | 3.1 | |
| Enterprise value over EBITDA | 87.91 | -22.7 | -194.63 | -29.35 | -34.66 | |
| EV to operating cash flow | -32.01 | -14.07 | -144.59 | -30.25 | -19.46 | |
| EV to free cash flow | -29.01 | -8.52 | -113.54 | -24.26 | -17.9 | |
| Earnings yield | -0.12 | -0.17 | -0.02 | -0.07 | -0.11 | |
| Free cash flow yield | -0.04 | -0.13 | -0.01 | -0.05 | -0.06 | |
| Debt to equity | 0.35 | 0.48 | 0.3 | 0.57 | 0.8 | |
| Debt to assets | 0.2 | 0.24 | 0.2 | 0.3 | 0.36 | |
| Net debt to EBITDA | 3.23 | -2.03 | -5.42 | -2.51 | -4.27 | |
| Current ratio | 1.85 | 1.31 | 1.32 | 0.98 | 0.77 | |
| Interest coverage | -0.05 | -3.17 | -3.07 | -2.79 | -2.22 | |
| Income quality | 0.28 | 0.44 | 0.46 | 0.53 | 0.56 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.05 | 0.04 | 0.03 | 0.03 | 0.02 | |
| Research and developement to revenue | 0.03 | 0.07 | 0.06 | 0.05 | 0.01 | |
| Intangibles to total assets | 0.08 | 0.14 | 0.1 | 0.12 | 0.21 | |
| Capex to operating cash flow | 0.1 | 0.65 | 0.27 | 0.25 | 0.09 | |
| Capex to revenue | -0.02 | -0.25 | -0.04 | -0.04 | -0.01 | |
| Capex to depreciation | -0.24 | -1.73 | -0.26 | -0.35 | -0.19 | |
| Stock based compensation to revenue | 0.02 | 0.03 | 0.05 | 0.03 | 0 | |
| Graham number | 8.07K | 6.48K | 4.63K | 3.5K | 3.76K | |
| ROIC | 0 | -0.14 | -0.09 | -0.14 | -0.14 | |
| Return on tangible assets | -0.19 | -0.25 | -0.09 | -0.14 | -0.26 | |
| Graham Net | 221.8 | -503.4 | 250.86 | -121.14 | -849.93 | |
| Working capital | 26.65B | 9.69B | 14.51B | -1.18B | -10.24B | |
| Tangible asset value | 70.82B | 55.3B | 96.65B | 53B | 28.59B | |
| Net current asset value | 9.71B | -15.75B | 9.78B | -4.07B | -24.83B | |
| Invested capital | 0.35 | 0.48 | 0.3 | 0.57 | 0.8 | |
| Average receivables | 21.9B | 28.23B | 18.93B | 18.03B | 12.43B | |
| Average payables | 293.04M | 1.01B | 1.51B | 1.54B | 1.37B | |
| Average inventory | 3.85B | 5.88B | 7.64B | 8.9B | 12.15B | |
| Days sales outstanding | 380.51 | 205.79 | 145.2 | 148.56 | 30.62 | |
| Days payables outstanding | 9 | 18.25 | 14.92 | 16.1 | 9.12 | |
| Days of inventory on hand | 82.84 | 85.99 | 81.12 | 98.53 | 115.09 | |
| Receivables turnover | 0.96 | 1.77 | 2.51 | 2.46 | 11.92 | |
| Payables turnover | 40.54 | 19.99 | 24.46 | 22.67 | 40.01 | |
| Inventory turnover | 4.41 | 4.24 | 4.5 | 3.7 | 3.17 | |
| ROE | -0.3 | -0.43 | -0.12 | -0.24 | -0.46 | |
| Capex per share | -27.19 | -274.64 | -42.41 | -47.26 | -26.11 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 223.65 | 427.84 | 483.9 | 536.41 | 436.92 | |
| Net income per share | -66.12 | -82.13 | -183.2 | -85.48 | -203.87 | |
| Operating cash flow per share | -128.31 | 0.94 | -171.44 | -82.7 | -46.88 | |
| Free cash flow per share | -133.66 | -14.83 | -175.08 | -88.04 | -48.24 | |
| Cash per share | 675.84 | 537.39 | 583.74 | 338.53 | 232.44 | |
| Book value per share | 1.51K | 1.59K | 1.46K | 1.29K | 1.17K | |
| Tangible book value per share | 1.25K | 910.27 | 783.54 | 704.42 | 674.69 | |
| Share holders equity per share | 1.51K | 1.59K | 1.46K | 1.29K | 1.17K | |
| Interest debt per share | 895.18 | 1.08K | 1.18K | 969.76 | 958.83 | |
| Market cap | 224.09B | 257.56B | 211.41B | 170.75B | 216.94B | |
| Enterprise value | 245.01B | 284.25B | 240.71B | 200.28B | 247.44B | |
| P/E ratio | -20 | -18.51 | -6.81 | -11.79 | -6.28 | |
| Price to sales ratio | 23.65 | 14.21 | 10.31 | 7.51 | 11.72 | |
| POCF ratio | -41.23 | 6.44K | -29.11 | -48.73 | -109.21 | |
| PFCF ratio | -39.58 | -410.07 | -28.5 | -45.77 | -106.14 | |
| P/B Ratio | 3.51 | 3.84 | 3.42 | 3.14 | 4.39 | |
| PTB ratio | 3.51 | 3.84 | 3.42 | 3.14 | 4.39 | |
| EV to sales | 25.86 | 15.68 | 11.74 | 8.81 | 13.37 | |
| Enterprise value over EBITDA | -57.58 | 34.22 | 25.86 | 20.17 | -315.73 | |
| EV to operating cash flow | -45.08 | 7.11K | -33.14 | -57.16 | -124.56 | |
| EV to free cash flow | -43.27 | -452.57 | -32.45 | -53.69 | -121.06 | |
| Earnings yield | -0.01 | -0.01 | -0.04 | -0.02 | -0.04 | |
| Free cash flow yield | -0.03 | 0 | -0.04 | -0.02 | -0.01 | |
| Debt to equity | 0.57 | 0.66 | 0.78 | 0.73 | 0.8 | |
| Debt to assets | 0.3 | 0.33 | 0.35 | 0.32 | 0.36 | |
| Net debt to EBITDA | -4.92 | 3.21 | 3.15 | 2.97 | -38.92 | |
| Current ratio | 0.98 | 0.9 | 0.86 | 0.9 | 0.77 | |
| Interest coverage | -4.45 | -2.08 | -3.45 | -1.56 | -1.89 | |
| Income quality | 1.94 | -0.01 | 0.86 | 0.87 | 0.23 | |
| Dividend Yield | 0 | 0 | 0.07 | 0.09 | 0 | |
| Payout ratio | 0 | 0 | -1.98 | -4.25 | 0 | |
| Sales general and administrative to revenue | 0.02 | 0.61 | 0.73 | 0.54 | 0.02 | |
| Research and developement to revenue | 0.14 | 0.02 | 0.01 | 0 | 0 | |
| Intangibles to total assets | 0.12 | 0.25 | 0.24 | 0.27 | 0.21 | |
| Capex to operating cash flow | 0.04 | -16.71 | 0.02 | 0.06 | 0.03 | |
| Capex to revenue | -0.02 | -0.04 | -0.01 | -0.01 | 0 | |
| Capex to depreciation | -0.13 | -0.46 | -0.1 | -0.15 | -0.04 | |
| Stock based compensation to revenue | 0.01 | 0 | 0 | 0 | 0 | |
| Graham number | 1.5K | 1.71K | 2.45K | 1.57K | 2.31K | |
| ROIC | -0.06 | -0.02 | -0.05 | -0.03 | -0.03 | |
| Return on tangible assets | -0.03 | -0.03 | -0.07 | -0.04 | -0.1 | |
| Graham Net | -120.83 | -521.24 | -638.16 | -717.81 | -849.85 | |
| Working capital | -1.18B | -5.01B | -7.79B | -4.27B | -10.24B | |
| Tangible asset value | 53B | 38.56B | 33.2B | 29.85B | 28.59B | |
| Net current asset value | -4.07B | -20.64B | -24.3B | -20.96B | -24.83B | |
| Invested capital | 0.57 | 0.66 | 0.78 | 0.73 | 0.8 | |
| Average receivables | 17.42B | 18.41B | 18.41B | 15.77B | 10.04B | |
| Average payables | 1.98B | 1.73B | 2.22B | 2.25B | 1.53B | |
| Average inventory | 10.13B | 10.01B | 11.61B | 12.45B | 13.25B | |
| Days sales outstanding | 172.42 | 92.74 | 79.67 | 53 | 32.58 | |
| Days payables outstanding | 16.35 | 17.02 | 20.82 | 13.39 | 10.56 | |
| Days of inventory on hand | 100.05 | 94.16 | 104.18 | 84.05 | 133.21 | |
| Receivables turnover | 0.52 | 0.97 | 1.13 | 1.7 | 2.76 | |
| Payables turnover | 5.51 | 5.29 | 4.32 | 6.72 | 8.52 | |
| Inventory turnover | 0.9 | 0.96 | 0.86 | 1.07 | 0.68 | |
| ROE | -0.04 | -0.05 | -0.13 | -0.07 | -0.17 | |
| Capex per share | -5.35 | -15.77 | -3.64 | -5.35 | -1.36 |
003580.KS Frequently Asked Questions
What is NEXT SCIENCE Co., Ltd. stock symbol ?
NEXT SCIENCE Co., Ltd. is a KR stock and trading under the symbol 003580.KS
What is NEXT SCIENCE Co., Ltd. stock quote today ?
NEXT SCIENCE Co., Ltd. stock price is $7230 today.
Is NEXT SCIENCE Co., Ltd. stock public?
Yes, NEXT SCIENCE Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 1.55M
- Market Capitalization 343.67B
- Employee 95
- CEO Mr. Dong-Su Lee
- Headquarters Sabuk-Eup,KR
- IPO Date 2000-01-04
-
Website
https://www.dongwoncorp.com 
HLB GLOBAL Co., Ltd. engages in the sea sand extraction business in South Korea. Its marine sand production process includes departure, extraction, berthing, discharging, sorting, washing, and shipment. The company also collects aggregates from under the sea, such as gravel, sand, mixed and fine aggregates, asphalt, concrete, and others. In addition, it offers a range of products, including color cosmetics, hair products, and denim jeans in the United States, China, and Japan. Further, the company develops drugs for infectious diseases, such as sepsis, influenza, and viral hepatitis; and immunological diseases, including rheumatoid arthritis and others. The company was formerly known as NEXT SCIENCE Co., Ltd. and changed its name to HLB GLOBAL Co., Ltd. in April 2022. HLB GLOBAL Co., Ltd. was founded in 1962 and is headquartered in Sabuk-eup, South Korea.
